Evidence map›Paper›PMID 41661647›Full record

ReviewHuman vaccines & immunotherapeutics2026

An overview of the clinical development of the 20-valent pneumococcal conjugate vaccine in adults.

Kathleen McElwee, Jelena Vojicic, Charulata Sabharwal, John Ginis, Yahong Peng, Gabriel Mircus, Wendy Watson, Annaliesa Anderson

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kathleen McElweePfizer Vaccines, Pfizer Inc, Collegeville, PA, USA.
Jelena VojicicPfizer Vaccines, Pfizer Inc, Collegeville, PA, USA.
Charulata SabharwalPfizer Vaccines, Pfizer Inc, Pearl River, NY, USA.
John GinisPfizer Vaccines, Pfizer Inc, Collegeville, PA, USA.
Yahong PengPfizer Vaccines, Pfizer Inc, Collegeville, PA, USA.
Gabriel MircusPfizer Vaccines, Pfizer Inc, Collegeville, PA, USA.
Wendy WatsonPfizer Vaccines, Pfizer Inc, Collegeville, PA, USA.
Annaliesa AndersonPfizer Vaccines, Pfizer Inc, Pearl River, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to expand protection against vaccine-preventable disease caused by

Indexed as

Pneumococcal InfectionsPneumococcal VaccinesVaccine DevelopmentAdolescentAdultAgedClinical Trials as TopicHumansMiddle AgedSerogroupStreptococcus pneumoniaeVaccine EfficacyVaccines, ConjugateYoung Adult13-valent pneumococcal vaccine23-valent pneumococcal capsular polysaccharide vaccinePneumococcal VaccinesVaccines, Conjugate20-valent pneumococcal conjugate vaccineAdultsclinical trialsimmunogenicitysafetyStreptococcus pneumoniae

Identifiers

PMID41661647
PMCPMC12893683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.